Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering

Biomaterials

Volumn 35, Issue 23, 2014, Pages 6106-6117

  Guo, Zhaoming ^a   He, Bing ^a   Jin, Hongwei ^a   Zhang, Haoran ^a   Dai, Wenbing ^a   Zhang, Liangren ^a   Zhang, Hua ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anticancer; Integrin v 3 clustering; Liposomes; RGD; Targeted delivery

Indexed keywords

LIPOSOMES; MOLECULAR BIOLOGY; REFRACTIVE INDEX; TUMORS;

ANTICANCER; CLATHRIN-DEPENDENT PATHWAY; INTEGRINS; NEAR-INFRARED FLUORESCENT; RGD; SINGLE-MOLECULE IMAGING; TARGETED DELIVERY; TOTAL INTERNAL REFLECTION FLUORESCENCE MICROSCOPY;

LIGANDS;

ARGINYLGLYCYLASPARTIC ACID; CLATHRIN; DIMER; LIGAND; LIPOSOME; MONOMER; NANOCARRIER; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; NANOCAPSULE; NANOCOMPOSITE; OLIGOPEPTIDE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; EX VIVO STUDY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; MALE; MCF 7 CELL LINE; MELANOMA B16; MOUSE; NANOTECHNOLOGY; NEAR INFRARED FLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; SURFACE PLASMON RESONANCE; TOTAL INTERNAL REFLECTION FLUORESCENCE MICROSCOPY; CHEMISTRY; COMPARATIVE STUDY; EXPERIMENTAL MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

HUMANS; INTEGRIN ALPHAVBETA3; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NANOCOMPOSITES; OLIGOPEPTIDES; PROTEIN BINDING;

EID: 84900032841     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.031     Document Type: Article

References (43)

1. Tam Y.Y., Chen S., Zaifman J., Tam Y.K., Lin P.J., Ansell S., et al. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine 2013, 9(5):665-674.
2. Hossen M.N., Kajimoto K., Akita H., Hyodo M., Ishitsuka T., Harashima H. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. JControl Release 2010, 147(2):261-268.
3. Zhao P., Lane T.R., Gao H.G., Hurst D.P., Kotsikorou E., Le L., et al. Crucial positively charged residues for ligand activation of the GPR35 receptor. JBiol Chem 2014, 289(6):3625-3638.
4. Ketchum C., Miller H., Song W., Upadhyaya A. Ligand mobility regulates B cell receptor clustering and signaling activation. Biophys J 2014, 106(1):26-36.
5. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338(6109):903-910.
6. Hunt K.K., Vorburger S.A. Tech.Sight. Gene therapy. Hurdles and hopes for cancer treatment. Science 2002, 297(5580):415-416.
7. Sako Y., Minoghchi S., Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2000, 2(3):168-172.
8. Welf E.S., Naik U.P., Ogunnaike B.A. Aspatial model for integrin clustering as a result of feedback between integrin activation and integrin binding. Biophys J 2012, 103(6):1379-1389.
9. Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L., et al. Architecture of Eph receptor clusters. Proc Natl Acad Sci U S A 2010, 107(24):10860-10865.
10. Wang Q., Dierkes R., Kaufmann R., Cremer C. Quantitative analysis of individual hepatocyte growth factor receptor clusters in influenza A virus infected human epithelial cells using localization microscopy. Biochim Biophys Acta 2014, 1838(4):1191-1198.
11. Caré B.R., Soula H.A. Impact of receptor clustering on ligand binding. BMC Syst Biol 2011, 5:48.
12. McQuade P., KnIght L.C. Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). QJ Nucl Med 2003, 47(3):209-220.
13. Chen X., Sievers E., Hou Y., Park R., Tohme M., Bart R., et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 2005, 7(3):271-279.
14. Seftor R.E., Seftor E.A., Gehlsen K.R., Stetler-Stevenson W.G., Brown P.D., Ruoslahti E., et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A 1992, 89(5):1557-1561.
15. Gladson C.L., Cheresh D.A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. JClin Invest 1991, 88(6):1924-1932.
16. Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001, 294(5541):339-345.
17. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296(5565):151-155.
18. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
19. Dijkgraaf I., Beer A.J., Wester H.J. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci (Landmark Ed) 2009, 14:887-899.
20. Beer A.J., Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008, 27(4):631-644.
21. Pike D.B., Ghandehari H. HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev 2010, 62(2):167-183.
22. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. JCell Biol 2010, 188(6):759-768.
23. Chen K., Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics 2011, 1:189-200.
24. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009, 20(12):2199-2213.
25. Liu Z., Shi J., Jia B., Yu Z., Liu Y., Zhao H., et al. Two [U+2079][U+2070]Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharmacol 2011, 8(2):591-599.
26. Shi J., Kim Y.S., Zhai S., Liu Z., Chen X., Liu S. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 2009, 20(4):750-759.
27. Du W., Fan Y., Zheng N., He B., Yuan L., Zhang H., et al. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013, 34(3):794-806.
28. Wang Z., Yu Y., Dai W., Cui J., Wu H., Yuan L., et al. Aspecific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials 2013, 34(3):756-764.
29. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012, 33(2):679-691.
30. Quinn J.G., O'Neill S., Doyle A., McAtamney C., Diamond D., MacCraith B.D., et al. Development and application of surface plasmon resonance-based biosensors for the detection of cell-ligand interactions. Anal Biochem 2000, 281(2):135-143.
31. Suga K., Umakoshi H. Detection of nanosized ordered domains in DOPC/DPPC and DOPC/Ch binary lipid mixture systems of large unilamellar vesicles using a TEMPO quenching method. Langmuir 2013, 29(15):4830-4838.
32. Chen C.W., Lu D.W., Yeh M.K., Shiau C.Y., Chiang C.H. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine 2011, 6:2567-2580.
33. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells. Biomaterials 2013, 34(22):5617-5627.
34. Peiris D., Markiv A., Curley G.P., Dwek M.V. Anovel approach to determining the affinity of protein-carbohydrate interactions employing adherent cancer cells grown on a biosensor surface. Biosens Bioelectron 2012, 35(1):160-166.
35. Chen Y., Wang S., Lu X., Zhang H., Fu Y., Luo Y. Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. Blood 2011, 117(23):6392-6403.
36. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011, 12(8):517-533.
37. Sancey L., Garanger E., Foillard S., Schoehn G., Hurbin A., Albiges-Rizo C., et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther 2009, 17(5):837-843.
38. Cluzel C., Saltel F., Lussi J., Paulhe F., Imhof B.A., Wehrle-Haller B. The mechanisms and dynamics of (alpha)v(beta)3 integrin clustering in living cells. JCell Biol 2005, 171(2):383-392.
39. Brinkerhoff C.J., Linderman J.J. Integrin dimerization and ligand organization: key components in integrin clustering for cell adhesion. Tissue Eng 2005, 11(5-6):865-876.
40. Gottschalk K.E., Kessler H. Acomputational model of transmembrane integrin clustering. Structure 2004, 12(6):1109-1116.
41. Yu Y.P., Wang Q., Liu Y.C., Xie Y. Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3. Biomaterials 2014, 35(5):1667-1675.
42. 64Cu-labeled tetrameric RGD peptide. JNucl Med 2005, 46(10):1707-1718.
43. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharmacol 2006, 3(5):472-487.